Named on one round in the feed.
Since 2022-06-13
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
Sling Therapeutics A biopharmaceutical company advancing oral linsitinib for thyroid eye disease | Series A Published on thinner evidence, 1 source[ HISTORY ]: An earlier round of this company, found through its checked dossier and read from its own announcement like any round. Not news: never sent, and left out of the feed unless you filter by date. | $35M | 2022-06-13 | [ LEAD ] |
No one else named on these rounds.